Skip to content
Screener

Xencor XNCR Investing Cash Flow

Investing Cash Flow at other companies

Amgen logo
AmgenAMGN
-$569M-46.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$92.7M+91.5%
Janux Therapeutics logo
Janux TherapeuticsJANX
-$38.78M
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$25.08M-416%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$34.98M+136%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$4.8M-6,990%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.6B+221%
Enterprise value$1.73B+159%
P/S15.3×+11.9×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from sales of marketable equity securities13,399
Proceeds from sales of marketable debt securities30,658
Proceeds from maturities of marketable debt securities154,966219,382
Net cash provided by investing activities111,79754,144
Cash flows from financing activities
Proceeds from the exercises of stock options9852,974
Proceeds from issuance of common stock under the Employee Stock Purchase Plan996662
Cash paid to acquire noncontrolling interest(1,725)

Item 1. Financial Statements

FAQ

What is Xencor's investing cash flow?
Xencor (XNCR) reported investing cash flow of $85.12M in Q2 2026.
How has Xencor's investing cash flow changed year-over-year?
Xencor's investing cash flow increased by 110.3% year-over-year, from $40.48M to $85.12M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Xencor's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude